Media coverage about Insys Therapeutics (NASDAQ:INSY) has been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Insys Therapeutics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 47.3385711394931 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Investors Purchase Large Volume of Put Options on Insys Therapeutics (INSY) (americanbankingnews.com)
- Here's Why Marijuana Stocks Got Crushed Today (finance.yahoo.com)
- Insys Therapeutics Inc (NASDAQ:INSY) Stock Overbought – Live … – Live Trading News (livetradingnews.com)
- INSYS Therapeutics Inc (NASDAQ:INSY) Takes A Dive – USMarketsDaily (blog) (usmarketsdaily.com)
- Why Buckle, Insys Therapeutics, and United Natural Foods Slumped Today – Motley Fool (fool.com)
Insys Therapeutics (NASDAQ:INSY) opened at $10.70 on Friday. The company has a market cap of $784.49, a price-to-earnings ratio of -4.20 and a beta of 0.76. Insys Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.02.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.com-unik.info/2018/01/07/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-insys-therapeutics-insy-share-price.html.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.